Skip to main content
PMC home page
Gut logoLink to Gut
. 1990 Mar;31(3):355–358. doi: 10.1136/gut.31.3.355

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.

G Dobrilla 1, B P Imbimbo 1, L Piazzi 1, G Bensi 1
PMCID: PMC1378284  PMID: 2182401

Abstract

The aim of this study was to evaluate the efficacy of cimetropium bromide, a new antimuscarinic compound, in relieving symptoms of patients with irritable bowel syndrome over a three month period. Seventy consecutive outpatients were given cimetropium (50 mg tid) or placebo according to a double blind, randomised, parallel groups design. Symptoms were evaluated initially and at monthly intervals up to the end of the study period. One patient receiving placebo withdrew because of treatment failure. Pain score decreased by 40, 66, 85% in the cimetropium group, at the end of the first, second and third months respectively, compared with 26, 32 and 52% reductions among controls (p = 0.0005). At the end of treatment there was a 86% reduction in the number of abdominal pain episodes per day in the cimetropium group compared with 50% in the placebo group (p = 0.001). Constipation and diarrhoea scores decreased by 59 and 49% in the cimetropium treated patients, compared with 37 and 39% in controls, the differences between being not significant. At the end of the study 89% of the patients treated with cimetropium considered themselves as globally improved as opposed to 69% in the placebo group (p = 0.039). The corresponding 95% confidence intervals for the differences between the proportion of improved patients in the two groups were from 11% to 29%. Six patients taking cimetropium complained of slight dry mouth. The results of this study showed that cimetropium bromide is effective in relieving pain in patients with irritable bowel syndrome.

Full text

PDF
355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassotti G., Imbimbo B. P., Gaburri M., Daniotti S., Morelli A. Transverse and sigmoid colon motility in healthy humans: effects of eating and of cimetropium bromide. Digestion. 1987;37(1):59–64. doi: 10.1159/000199488. [DOI] [PubMed] [Google Scholar]
  2. Centonze V., Imbimbo B. P., Campanozzi F., Attolini E., Daniotti S., Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol. 1988 Nov;83(11):1262–1266. [PubMed] [Google Scholar]
  3. Drossman D. A., Lowman B. C. Irritable bowel syndrome: epidemiology, diagnosis and treatment. Clin Gastroenterol. 1985 Jul;14(3):559–573. [PubMed] [Google Scholar]
  4. Drossman D. A., Sandler R. S., McKee D. C., Lovitz A. J. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982 Sep;83(3):529–534. [PubMed] [Google Scholar]
  5. Fielding J. F. Domperidone treatment in the irritable bowel syndrome. Digestion. 1982;23(2):125–127. doi: 10.1159/000198701. [DOI] [PubMed] [Google Scholar]
  6. Fielding J. F. Timolol treatment in the irritable bowel syndrome. Digestion. 1981;22(3):155–158. doi: 10.1159/000198627. [DOI] [PubMed] [Google Scholar]
  7. Gardner M. J., Altman D. G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):746–750. doi: 10.1136/bmj.292.6522.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Imbimbo B. P., Daniotti S., Vidi A., Foschi D., Saporiti F., Ferrante L. Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. J Pharm Sci. 1986 Jul;75(7):680–684. doi: 10.1002/jps.2600750713. [DOI] [PubMed] [Google Scholar]
  9. Imbimbo B. P., Piperno A., Fiorelli G., Muzio F., Daniotti S. Urinary excretion of cimetropium bromide after multiple oral doses. Eur J Clin Pharmacol. 1987;33(3):337–338. doi: 10.1007/BF00637575. [DOI] [PubMed] [Google Scholar]
  10. Ivey K. J. Are anticholinergics of use in the irritable colon syndrome? Gastroenterology. 1975 May;68(5 Pt 1):1300–1307. [PubMed] [Google Scholar]
  11. Klein K. B. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 1988 Jul;95(1):232–241. doi: 10.1016/0016-5085(88)90319-8. [DOI] [PubMed] [Google Scholar]
  12. Lanfranchi G. A., Bazzocchi G., Campieri M., Brignola C., Fois F., Imbimbo B. P. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Eur J Clin Pharmacol. 1988;33(6):571–575. doi: 10.1007/BF00542489. [DOI] [PubMed] [Google Scholar]
  13. Litta-Modignani R., Mazzolari M., Barantani E., Bertoli D., Vibelli C. Relative potency of the atropine-like effects of a new parasympatholytic drug, scopolamine-N-(cyclopropyl methyl) bromide and those of hyoscine-N-butyl bromide. Curr Med Res Opin. 1977;5(4):333–340. doi: 10.1185/03007997709110189. [DOI] [PubMed] [Google Scholar]
  14. Longstreth G. F., Fox D. D., Youkeles L., Forsythe A. B., Wolochow D. A. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med. 1981 Jul;95(1):53–56. doi: 10.7326/0003-4819-95-1-53. [DOI] [PubMed] [Google Scholar]
  15. Oettlé G. J., Heaton K. W. Is there a relationship between symptoms of the irritable bowel syndrome and objective measurements of large bowel function? A longitudinal study. Gut. 1987 Feb;28(2):146–149. doi: 10.1136/gut.28.2.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Passaretti S., Guslandi M., Imbimbo B. P., Daniotti S., Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1989 Jun;3(3):267–276. doi: 10.1111/j.1365-2036.1989.tb00213.x. [DOI] [PubMed] [Google Scholar]
  17. Prout B. J. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner. 1983 Oct;227(1384):1607–1608. [PubMed] [Google Scholar]
  18. Ritchie J. A., Truelove S. C. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J. 1979 Feb 10;1(6160):376–378. doi: 10.1136/bmj.1.6160.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sagrada A., Schiavone A., Cefalà A., Micheletti R. Cimetropium bromide: in vitro and in vivo evaluation of spasmolytic activity on human and dog colon. Digestion. 1989;42(3):143–150. doi: 10.1159/000199839. [DOI] [PubMed] [Google Scholar]
  20. Schiavone A., Schiavi G. B., De Conti L., Micheletti R., Sagrada A., Hammer R., Giachetti A. Cimetropium: characterization of antimuscarinic and spasmolytic properties. Arzneimittelforschung. 1985;35(5):796–799. [PubMed] [Google Scholar]
  21. Thompson W. G. Irritable bowel syndrome: prevalence, prognosis and consequences. CMAJ. 1986 Jan 15;134(2):111–113. [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES